Search

Displaying results 5551 - 5560 of 10000 in total
  1. Drug

    Coumermycin A1

    go.drugbank.com/drugs/DB13912
    Experimental

    Categories: Topoisomerase II Inhibitors
  2. Drug

    Cilazaprilat

    go.drugbank.com/drugs/DB15565
    Experimental

    Categories: Agents Acting on the Renin-Angiotensin System
  3. Drug

    Davunetide

    go.drugbank.com/drugs/DB12613
    Investigational

    Davunetide is the first drug to improve memory performance by impacting the mechanisms that lead to physical damage in the brain caused by neurofibrillary tangles, one of the two established pathological … Davunetide has been used in trials studying the treatment of Progressive Nonfluent Aphasia, Progressive Supranuclear Palsy, Predicted Tauopathies, Including, Corticobasal Degeneration Syndrome, and Frontotemporal

  4. Drug

    Vibriolysin

    go.drugbank.com/drugs/DB05135
    Experimental

    It is a new agent for enzymatic debridement, shown to rapidly and thoroughly hydrolyze burn wound eschar within full-thickness wounds. … Vibriolysin is a proteolytic enzyme secreted by the marine microorganism Vibrio proteolyticus.

  5. Drug

    Namilumab

    go.drugbank.com/drugs/DB13037
    Investigational

    Namilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.

  6. Drug

    Ribostamycin

    go.drugbank.com/drugs/DB03615
    ApprovedWithdrawn

    Ribostamycin is an aminoglycoside antibiotic[A187166] isolated from _Streptomyces ribosidificus_[A187178] listed as one of the World Health Organization's critically important antimicrobials.[L9071]

  7. Drug

    Desidustat

    go.drugbank.com/drugs/DB16135
    Investigational

    Desidustat is under investigation in clinical trial NCT04012957 (Desidustat in the Treatment of Anemia in CKD).

  8. Drug

    VTP-201227

    go.drugbank.com/drugs/DB05652
    Experimental

    It is being developed by Vitae Pharmaceuticals. … VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications.

  9. Drug

    Foslevodopa

    go.drugbank.com/drugs/DB16683
    Approved

    Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants

  10. Drug

    Sarconeos

    go.drugbank.com/drugs/DB16457
    Investigational

    Sarconeos is an activator of the MAS receptor.